**PUBLICATION NUMBER** 

05331070

PUBLICATION DATE

14-12-93

APPLICATION DATE

05-02-93

**APPLICATION NUMBER** 

05018489

APPLICANT: TAKEDA CHEM IND LTD:

INVENTOR: SUDO KATSUICHI;

INT.CL.

A61K 37/02 A61K 31/335 A61K 31/70

TITLE

ANTINEOPLASTIC AGENT

CONTAINING BOTH TNP AND

**INTERLEUKIN** 

 $CH_2R^2$ CH2R3

N(O)mR<sup>5</sup>R<sup>6</sup>

П

ABSTRACT: PURPOSE: To provide an antineoplastic agent having excellent metastasis inhibitory activity and the life prolongation effect on cancer-bearing animals at extremely low doses, consisting of a combination of a fumagillin derivative or a salt thereof and interleukin.

CONSTITUTION: The antineoplastic agent consisting of a combination of (A) a compound

of formula i [R1 is H; R2 is halogen, of formula II (R5

and R<sup>6</sup> are each (substituted) hydrocarbon or heterocyclic group; m is 0 or 1),

etc.; or, R1 and R2 are combined into a lone bond; R3 is 2-methyl-1-propenyl or isobutyl; A is 0 or NR8 (R8 is H.

(substituted) lower alkyl, etc.); R<sup>4</sup> is H, acyl, etc.] having vascularization

inhibitory activity [e.g. 6-O-(N-methylcarbamoyl) fumagillol] and (B) an interleukin (pref.

interleukin-2).



**PUBLICATION NUMBER** 

05331070

**PUBLICATION DATE** 

14-12-93

**APPLICATION DATE** 

05-02-93

**APPLICATION NUMBER** 

05018489

APPLICANT: TAKEDA CHEM IND LTD:

INVENTOR: SUDO KATSUICHI;

INT.CL.

A61K 37/02 A61K 31/335 A61K 31/70

TITLE

: ANTINEOPLASTIC AGENT

CONTAINING BOTH TNP AND

INTERLEUKIN

CH<sub>2</sub>R<sup>3</sup>

N(O)mR<sup>5</sup> R<sup>6</sup>

П

ABSTRACT :

PURPOSE: To provide an antineoplastic agent having excellent metastasis inhibitory activity and the life prolongation effect on cancer-bearing animals at extremely low doses, consisting of a combination of a fumagillin derivative or a salt thereof and interleukin.

CONSTITUTION: The antineoplastic agent consisting of a combination of (A) a compound

of formula i [R1 is H; R2 is halogen, of formula II (R5

and R<sup>6</sup> are each (substituted) hydrocarbon or heterocyclic group; m is 0 or 1),

etc.; or, R1 and R2 are combined into a lone bond; R3 is 2-methyl-1-propenyl or isobutyl; A is 0 or NR8 (R8 is H.

(substituted) lower alkyl, etc.); R4 is H, acyl, etc.] having vascularization

inhibitory activity [e.g. 6-O-(N-methylcarbamoyl) fumagillol] and (B) an interleukin (pref.

interleukin-2).



**PUBLICATION NUMBER** 

05331070

**PUBLICATION DATE** 

14-12-93

APPLICATION DATE

05-02-93

**APPLICATION NUMBER** 

05018489

APPLICANT: TAKEDA CHEM IND LTD:

INVENTOR: SUDO KATSUICHI;

INT.CL.

A61K 37/02 A61K 31/335 A61K 31/70

TITLE

: ANTINEOPLASTIC AGENT

**CONTAINING BOTH TNP AND** 

**INTERLEUKIN** 

CH<sub>2</sub>R<sup>8</sup>

N(O)mR<sup>5</sup>R<sup>6</sup>

П

ABSTRACT: PURPOSE: To provide an antineoplastic agent having excellent metastasis inhibitory activity and the life prolongation effect on cancer-bearing animals at extremely low doses, consisting of a combination of a fumagillin derivative or a salt thereof and interleukin.

> CONSTITUTION: The antineoplastic agent consisting of a combination of (A) a compound of formula i [R1 is H; R2 is halogen, of formula II (R5

and R<sup>6</sup> are each (substituted) hydrocarbon or heterocyclic group; m is 0 or 1),

etc.; or, R1 and R2 are combined into a lone bond; R3 is 2-methyl-1-propenyl or isobutyl; A is 0 or NR8 (R8 is H,

(substituted) lower alkyl, etc.); R4 is H, acyl, etc.] having vascularization

inhibitory activity [e.g. 6-O-(N-methylcarbamoyl) fumagillol] and (B) an interleukin (pref.

interleukin-2).



PUBLICATION NUMBER

05331070

PUBLICATION DATE

14-12-93

APPLICATION DATE

05-02-93

**APPLICATION NUMBER** 

05018489

APPLICANT: TAKEDA CHEM IND LTD:

INVENTOR: SUDO KATSUICHI;

INT.CL.

A61K 37/02 A61K 31/335 A61K 31/70

TITLE

: ANTINEOPLASTIC AGENT

CONTAINING BOTH TNP AND

**INTERLEUKIN** 

CH2R3  $R^1\Omega$ 

N(O)mR<sup>5</sup>R<sup>6</sup>

П

ABSTRACT: PURPOSE: To provide an antineoplastic agent having excellent metastasis inhibitory activity and the life prolongation effect on cancer-bearing animals at extremely low doses, consisting of a combination of a fumagillin derivative or a salt thereof and interleukin.

CONSTITUTION: The antineoplastic agent consisting of a combination of (A) a compound

of formula i [R1 is H; R2 is halogen, of formula II (R5

and R<sup>6</sup> are each (substituted) hydrocarbon or heterocyclic group; m is 0 or 1),

etc.; or, R<sup>1</sup> and R<sup>2</sup> are combined into a lone bond; R<sup>3</sup> is 2-methyl-1-propenyl or isobutyl; A is 0 or NR8 (R8 is H,

(substituted) lower alkyl, etc.); R4 is H, acyl, etc.] having vascularization

inhibitory activity [e.g. 6-O-(N-methylcarbamoyl) fumagillol] and (B) an interleukin (pref.

interleukin-2).



PUBLICATION NUMBER

05331070

PUBLICATION DATE

14-12-93

APPLICATION DATE

05-02-93

APPLICATION NUMBER

05018489

APPLICANT: TAKEDA CHEM IND LTD;

INVENTOR:

SUDO KATSUICHI;

INT.CL.

A61K 37/02 A61K 31/335 A61K 31/70

TITLE

: ANTINEOPLASTIC AGENT

CONTAINING BOTH TNP AND

INTERLEUKIN

CH<sub>2</sub>R<sup>2</sup> CH<sub>s</sub> CH<sub>2</sub>R<sup>s</sup>

N(O)mR<sup>5</sup>R<sup>6</sup>

П

ABSTRACT: PURPOSE: To provide an antineoplastic agent having excellent metastasis inhibitory activity and the life prolongation effect on cancer-bearing animals at extremely low doses, consisting of a combination of a fumagillin derivative or a salt thereof and interleukin.

CONSTITUTION: The antineoplastic agent consisting of a combination of (A) a compound

of formula i [R1 is H; R2 is halogen, of formula II (R5

and R<sup>6</sup> are each (substituted) hydrocarbon or heterocyclic group; m is 0 or 1),

etc.; or, R1 and R2 are combined into a lone bond; R3 is 2-methyl-1-propenyl or isobutyl; A is 0 or NR8 (R8 is H,

(substituted) lower alkyl, etc.); R4 is H, acyl, etc.] having vascularization

inhibitory activity [e.g. 6-O-(N-methylcarbamoyl) fumagillol] and (B) an interleukin (pref.

interleukin-2).